By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Prometheus Laboratories Inc. 

5739 Pacific Center Boulevard

San Diego  California  92121-4203  U.S.A.
Phone: 888-423-5227 Fax: 858-824-0896



Company News
Prometheus Laboratories Inc. Release: Introducing PROMETHEUS IBcause: Convenient All-In-One Diagnostic Test For Persistent Diarrhea 3/28/2017 8:57:46 AM
Prometheus Laboratories Inc. Release: PROMETHEUS Anser VDZ Test Validated For Use In Inflammatory Bowel Disease Patients 10/12/2016 7:26:28 AM
Prometheus Laboratories Inc. Diagnostic Test Validated In Anticipation Of U.S. Healthcare Provider Demand For Celltrion's INFLECTRA (Biosimilar Infliximab) 4/8/2016 9:55:30 AM
Prometheus Laboratories Inc. Release: PROCLAIM Patient Registry Data Demonstrate Survival Benefit Of First-Line Proleukin Therapy In Patients With Metastatic Renal Cell Carcinoma 5/28/2015 6:48:38 AM
Prometheus Laboratories Inc. Release: PROCLAIM Patient Registry Data Demonstrates Safety And Efficacy Of Proleukin (Aldesleukin) When Sequenced With Immune Checkpoint Inhibitors In Metastatic Melanoma 5/28/2015 6:30:18 AM
Prometheus Laboratories Inc. Release: New Data Show Proleukin (aldesleukin) Improves Patient Outcomes As First-Line Therapy For The Treatment Of Patients With Metastatic Melanoma Or Metastatic Renal Cell Carcinoma 5/15/2015 6:15:44 AM
Prometheus Laboratories Inc. Release: PROCLAIM Patient Registry Data Show Extension Of Overall Survival Benefits Beyond Complete And Partial Responders In Metastatic Renal Cell Carcinoma Patients Treated With High-Dose Interleukin-2 (HD IL-2) 5/30/2014 9:02:01 AM
Prometheus Laboratories Inc. Announces Inclusion of Proleukin® (Aldesleukin for Injection) / Interleukin-2 in SITC Guidelines for Treatment of Cutaneous Melanoma 10/11/2013 8:40:01 AM
Prometheus Laboratories Inc. Appoints Chief Executive Officer 9/19/2013 7:18:13 AM
Prometheus Laboratories Inc. Launches PROCLIVITY 02, a Phase IV Multi-Center Study Comparing the Sequence of Proleukin® (Aldesleukin for Injection) and Yervoy® (Ipilimumab) in Patients With Metastatic Melanoma 5/30/2013 10:41:58 AM